Compare Teladoc Health, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,093 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.20
-9.12%
0.79
Revenue and Profits:
Net Sales:
626 Million
(Quarterly Results - Sep 2025)
Net Profit:
-50 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-41.32%
0%
-41.32%
6 Months
-32.04%
0%
-32.04%
1 Year
-57.0%
0%
-57.0%
2 Years
-75.09%
0%
-75.09%
3 Years
-84.95%
0%
-84.95%
4 Years
-93.66%
0%
-93.66%
5 Years
-98.34%
0%
-98.34%
Teladoc Health, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
28.83%
EBIT Growth (5y)
-219.83%
EBIT to Interest (avg)
-13.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.25
Sales to Capital Employed (avg)
0.82
Tax Ratio
1.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
97.52%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.89
EV to EBIT
-8.76
EV to EBITDA
8.80
EV to Capital Employed
0.92
EV to Sales
0.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-10.45%
ROE (Latest)
-10.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 67 Schemes (36.63%)
Foreign Institutions
Held by 203 Foreign Institutions (19.49%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
626.40
640.50
-2.20%
Operating Profit (PBDIT) excl Other Income
56.70
51.50
10.10%
Interest
4.50
5.70
-21.05%
Exceptional Items
-16.50
-4.00
-312.50%
Consolidate Net Profit
-49.50
-33.30
-48.65%
Operating Profit Margin (Excl OI)
-56.60%
-63.00%
0.64%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -2.20% vs -2.98% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -48.65% vs 41.68% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,569.60
2,602.40
-1.26%
Operating Profit (PBDIT) excl Other Income
174.10
140.80
23.65%
Interest
23.80
22.30
6.73%
Exceptional Items
-812.10
-38.10
-2,031.50%
Consolidate Net Profit
-1,001.20
-220.40
-354.26%
Operating Profit Margin (Excl OI)
-81.30%
-80.90%
-0.04%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.26% vs 8.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -354.26% vs 98.39% in Dec 2023
About Teladoc Health, Inc. 
Teladoc Health, Inc.
Pharmaceuticals & Biotechnology
Teladoc Health, Inc. provides virtual healthcare services. The Company provides virtual access to care with a portfolio of services and solutions, which includes various medical subspecialties from non-urgent, episodic needs, such as flu and upper respiratory infections, to chronic, complicated medical conditions, such as cancer and congestive heart failure. It provides virtual healthcare services on a business-to-business (B2B) basis to its clients and provides services to consumers directly and through channel partners. The Company’s consumer brands, including Teladoc, Advance Medical, Best Doctors, BetterHelp and HealthiestYou, provides access to advice and resolution to a range of healthcare needs. Its technology enables consumers to manage their own electronic medical records. It also provides access to a message center, provider finder, image upload capability and enable real-time sharing capabilities with providers that includes visit scheduling.
Company Coordinates 
Company Details
2 Manhattanville Rd Ste 203 , PURCHASE NY : 10577-2118
Registrar Details






